Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Only 200 shares traded @ 10:15

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Sep 11, 2022 10:04am

175 Views

Post# 34955030

RE:RE:RE:Only 200 shares traded @ 10:15

GoldenInvestor wrote: Thanks! I figured it wasn't but was curious why nothing had traded , just 200 shares u til >+45 mins in.

it seemed stranger then picked up thereafter

I missed that - was on a train going to the Antibe AGM.

Just love the potential at ATE for GUD shareholders - got my fingers crossed for a future of opportunity there. Wouldn't surprise me if GUD's shelf prospectus is earmarked for the 346 asset in LATAM. Maybe - maybe not. Time will tell.

BTW ... Phase 2 346 in acute pain starts in late September (3rd Molar Extraction). Readout before Christmas. If that goes to plan, P2 Bunionectomies start in H1 2023.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload